$LAHO The Smart Money Is Piling Into Regenerative Medicine
Progressive Approval Could Be a Game Changer for RM Investing in Regenerative Medicine
The Goldman report discusses Samumed, a private RM company. With $300 million in funding,it’s valued at a staggering $12 billion Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.